France Non-Alcoholic Steatohepatitis Treatment Market (2025-2031) | Value, Trends, Industry, Analysis, Growth, Companies, Segmentation, Outlook, Forecast, Size & Revenue, Competitive Landscape, Share

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 France Country Macro Economic Indicators

3.2 France Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume, 2021 & 2031F

3.3 France Non-Alcoholic Steatohepatitis Treatment Market - Industry Life Cycle

3.4 France Non-Alcoholic Steatohepatitis Treatment Market - Porter's Five Forces

3.5 France Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume Share, By Drug Type, 2021 & 2031F

3.6 France Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume Share, By End-use, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of non-alcoholic steatohepatitis (NASH) in France

4.2.2 Rising awareness about NASH and its treatment options

4.2.3 Technological advancements in NASH treatment

4.2.4 Government initiatives to tackle NASH

4.2.5 Growing investments in research and development for NASH treatment

4.3 Market Restraints

4.3.1 High cost associated with NASH treatment

4.3.2 Stringent regulatory requirements for NASH drugs

4.3.3 Limited availability of approved treatment options for NASH

4.3.4 Lack of skilled healthcare professionals specialized in NASH treatment

4.3.5 Potential side effects and safety concerns of NASH medications

6.1 France Non-Alcoholic Steatohepatitis Treatment Market, By Drug Type

6.1.1 Overview and Analysis

6.1.2 France Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume, By Drug Type, 2021- 2031F

6.1.3 France Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume, By Vitamin E and Pioglitazone, 2021- 2031F

6.1.4 France Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume, By Obeticholic Acid (OCA), 2021- 2031F

6.1.5 France Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume, By Lanifibranor, 2021- 2031F

6.1.6 France Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume, By Semaglutide, 2021- 2031F

6.1.7 France Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume, By Resmetirom, 2021- 2031F

6.1.8 France Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume, By Aramchol, 2021- 2031F

6.1.9 France Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume, By Others, 2021- 2031F

6.1.10 France Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume, By Others, 2021- 2031F

6.2 France Non-Alcoholic Steatohepatitis Treatment Market, By End-use

6.2.1 Overview and Analysis

6.2.2 France Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F

6.2.3 France Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume, By Retail and Specialty Pharmacies, 2021- 2031F

6.2.4 France Non-Alcoholic Steatohepatitis Treatment Market Revenues & Volume, By Others, 2021- 2031F

7.1 France Non-Alcoholic Steatohepatitis Treatment Market Export to Major Countries

7.2 France Non-Alcoholic Steatohepatitis Treatment Market Imports from Major Countries

8.1 Patient enrollment in clinical trials for NASH treatments

8.2 Number of NASH treatment centers or clinics in France

8.3 Research and development expenditure on NASH treatment innovations

8.4 Adoption rate of new NASH treatment technologies or therapies

8.5 Number of collaborations or partnerships between pharmaceutical companies and research institutions for NASH treatment development

9.1 France Non-Alcoholic Steatohepatitis Treatment Market Opportunity Assessment, By Drug Type, 2021 & 2031F

9.2 France Non-Alcoholic Steatohepatitis Treatment Market Opportunity Assessment, By End-use, 2021 & 2031F

10.1 France Non-Alcoholic Steatohepatitis Treatment Market Revenue Share, By Companies, 2024

10.2 France Non-Alcoholic Steatohepatitis Treatment Market Competitive Benchmarking, By Operating and Technical Parameters